News
| Date | Subject |
| 2024-06 | Successfully achieved mass production of cosmetic-grade dissolvable microneedles. |
| 2024-05 | Completed the patent valuation for male pattern baldness technology and licensed it to |
| Sanar Biotech. | |
| 2024-01 | Awarded grant funding of $34M NTD for “Phase II Clinical Study Program for Wound |
| Therapy Protein Drug BB-101” from the Department of Industrial Technology (DOIT), | |
| Ministry of Economic Affairs (MOEA). | |
| 2023-06 | BB-101, a protein drug that promotes wound healing, has been approved by the Taiwan |
| FDA for clinical trials and will begin Phase II clinical trials at three medical centers in Taiwan | |
| 2023-03 | BB-101, a protein drug that promotes wound healing, applied to the Taiwan FDA for |
| Phase II clinical trials | |
| 2023-01 | BB-101, a protein drug that promotes wound healing, applied to the US FDA for the clinical |
| trials of phase II | |
| 2022 | Big Technology Group entrusts the development and analysis of peptide products |
| 2022 | The results of phase I clinical trial show that the BB-101 drug can effectively |
| improve the DFU in wound size and degree at both dosage | |
| 2022 | Entrust a medical factory to develop microneedle products for cosmetics’ application |
| 2022 | International Cosmetic Ingredients INCI listed |
| 2022 | Extending business to pet skin care by entrusted GMP factory to manufacture |
| high-efficiency pet skin rejuvenation spray | |
| 2021 | Complete the recruitment of subjects for the phase I clinical trial of BB-101, and the results |
| concludedthat the trial had no safety concerns by the committee board of Clinical Safety | |
| Monitoring. | |
| 2020 | Completed cGMP manufacturing at 300L for drug substance of clinical batch |
| 2020 | Completed engineering run at 500L scale for recombinant protein manufacture |
| 2018-05- | Taiwan FDA Approves Phase I Clinical Trial of NEGF (BB-101) for the |
| Treatment of Diabetic Foot Ulcers. | |
| 2018-05-23 | Patent application of “A composition for wound healing and use thereof” |
| was granted by European Patent Office. | |
| 2018-04-11 | Awarded grant funding of $15M NTD for “Phase I Clinical Study Program |
| for Wound Therapy Protein Drug BB-101” from Department of Industrial | |
| Technology of MOEA. | |
| 2015-11-24 | US FDA Approves Phase I Clinical Trial of NEGF (BB-101) for the |
| Treatment of Diabetic Foot Ulcers. | |
| From drug discovery to clinical trial, all the development works of BB-101 | |
| Blue Blood. FDA’s approval for clinical trial is an important milestone not only for Blue | |
| is executed by Blue Blood. FDA’s approval for clinical trial is an important | |
| milestone not only for Blue Blood, but also for Taiwan Biotechnology | |
| Industry. | |
| 2013-06-21 | Patent application of “A composition for wound healing and use thereof” was granted by |
| Taiwan Intellectual Property Office | |
| 2013-06-11 | Patent application of “Methods and compositions for bactericide, bacteriostatic and |
| anti-inflammation” was granted by Japan Patent Office | |
| 2013-05-28 | Patent application of “Methods and compositions for bactericide, bacteriostatic and |
| anti-inflammation” was granted by Korean Intellectual Property Office | |
| 2013-05-20 | The ongoing NEGF protein preclinical study was successfully awarded the Industrial |
| R&D Promotional Loans of 27 Million NT Dollars from Industrial Development | |
| Bureau, Ministry of Economic Affairs | |
| 2013-03-05 | In collaboration with Charles River Laboratories, U.S.A, BlueBlood effectively conducted |
| the 28-day repeat dose dermal toxicity study in mini-pigs | |
| 2013-02-05 | BlueBlood has partnered with Dow Pharmaceuticals Sciences (U.S.A) on GMP |
| manufacturing of Phase I clinical supplies |
－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－
| 2012-10-23 | Patent application of “Method for treating wounds using an EGF-like domain of |
| Thrombomodulin” was granted by United States Patent and Trademark Office | |
| 2012-10-23 | Patent application of “Methods and compositions for treating ischemia” was |
| granted by United States Patent and Trademark Office | |
| 2012-09-17 | Awarded grant funding of $15m NTD for “Preclinical Study Program for Wound |
| Therapy Protein Drug BB-101” from Department of Industrial Technology of MOEA | |
| 2012-07-16 | Engaged Associate Professor Chuan-Liang Kao as technical consultant in developing |
| Neutralization assay and antibody screening diagnostic kit for Cytomegalovirus | |
| 2012-06-12 | Conducted a GLP-compliance study: “A 28-day Study of NEGF by Subcutaneous |
| Injection in Rats with a 16-day Recovery Period” at Charles River Laboratories Inc | |
| 2012-06-11 | Patent application of “Methods and compositions for bactericide, bacteriostatic |
| and anti-inflammation” was granted by Taiwan Intellectual Property Office | |
| 2012-04-01 | Patent application of “Methods and compositions for bactericide, bacteriostatic |
| and anti-inflammation” was granted by European Patent Office |
－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－－
| 2011-11-30 | Patent application of “Methods and compositions for bactericide,bacteriostatic |
| and anti-inflammation” was granted by Intellectual Property Office of Singapore | |
| 2011-11-16 | Attend pre-IND meeting with US FDA for topical recombinant NEGF (BB-101) |
| and anti-inflammation” was granted by Intellectual Property Office of Singapore | |
| 2011-09-06 | Patent application of “A composition for wound healing and use thereof” was granted |
| by Japan Patent Office | |
| 2011-05-10 | Patent application of “Dextromethorphan-Based Method for Treating Acne” was |
| granted by United States Patent and Trademark Office | |
| 2011-04-28 | Patent application of “A composition for wound healing and use thereof” was granted |
| by Korean Intellectual Property Office | |
| 2011-04-05 | Patent application of “Methods and compositions for bactericide, bacteriostatic and |
| anti-inflammation” was granted by IP Australia |